Drug Patents owned by Genus Lifesciences

1. Drug name - GOPRELTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10933060 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US10973811 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US10987347 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US10894012 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US10857095 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US10231961 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US11040032 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US10016407 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US9867815 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US10413505 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US10420760 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

US10149843 GENUS LIFESCIENCES Pharmaceutical compositions and methods of using the same Feb, 2037

(14 years from now)

Drugs and Companies using COCAINE HYDROCHLORIDE ingredient

Treatment: Method for the induction of local anesthesia of the mucous membranes; Method of administering a local anesthetic to the mucous membranes in patients with renal impairment; Method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment; Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment; Method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment; method of administering a local anesthetic to the mucous membranes in patients with renal impairment; method of administering a local anesthetic to the mucous membranes in geriatric patients; Method of administering a local anesthetic to the mucous membranes; Method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes; Method of administering a local anesthetic to the mucous membranes; method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes

Dosage: SOLUTION;NASAL

More Information on Dosage
Strength Dosage Availability
4% SOLUTION;NASAL Prescription

2. Drug name - LEVOLET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10231931 GENUS LIFESCIENCES Thyroid hormone oral dosage forms and methods of using the same Mar, 2038

(15 years from now)

US10406108 GENUS LIFESCIENCES Thyroid hormone oral dosage forms and methods of using the same Mar, 2038

(15 years from now)

More Information on Dosage
Strength Dosage Availability
0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription
0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL Prescription

3. Drug name - YOSPRALA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6926907 GENUS LIFESCIENCES Pharmaceutical compositions for the coordinated delivery of NSAIDs Feb, 2023

(4 months from now)

US8206741 GENUS LIFESCIENCES Pharmaceutical compositions for the coordinated delivery of NSAIDs Feb, 2023

(4 months from now)

US9987231 GENUS LIFESCIENCES Compositions and methods for delivery of omeprazole plus acetylsalicylic acid Jan, 2033

(10 years from now)

US9539214 GENUS LIFESCIENCES Compositions and methods for delivery of omeprazole plus acetylsalicylic acid Mar, 2033

(10 years from now)

Drugs and Companies using ASPIRIN; OMEPRAZOLE ingredient

Treatment: Treatment or secondary prevention of cardiovascular disease, cardiovascular events, or cerebrovascular events and risk-reduction of aspirin-associated gastric ulcers; For secondary prevention of cardiovascular and cerebrovascular events in patients at risk of developing aspirin-associated gastric ulcers

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
81MG;40MG TABLET, DELAYED RELEASE;ORAL Discontinued
325MG;40MG TABLET, DELAYED RELEASE;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.